-
Enterococcus used to be considered the caboose of pathogens; maybe it mattered, but it still was at the far rear.
-
A retrospective review of one major continental United States (CONUS) tertiary care medical center's plastic surgery department's experience in the management of combat wounds was performed and included all cases seen between April 2003 and December 2005. Of the 68 patients treated, 16.2% sustained injuries to the head/face/neck, 61.8% had lower extremity injuries, 29.4% had upper extremity injuries, 15.6% had both upper and lower extremity injuries, and 35.9% had multiple sites of injuries.
-
Faced with limited data about acute mountain sickness in children who travelled rapidly to high altitudes, Swiss researchers studied symptoms in 48 children (ages 10-17, mean age 13) who traveled 2.5 hours from low altitude (568 meters) to 3,450 meters (approximately 11,200 feet).
-
In this issue: Individualization of therapy with pharmacogenetics; the rate vs rhythm debate; the FDA's Risk Evaluation and Mitigation Strategy; FDA actions.
-
Nucleic acid tests (NAA) for the diagnosis of pulmonary tuberculosis (TB) have had FDA approval for more than a decade, but their use has been limited, at least in part because of a frequent lack of availability in local laboratories.
-
The Merck integrase inhibitor, raltegravir, was studied in two identical trials in different geographic locations to evaluate its safety and efficacy vs placebo in combination with optimized background therapy in patients infected with 3-drug class-resistant (3DCR) HIV-1.
-
At the 57th annual meeting of the Aamerican Society of Tropical Medicine and Hygiene in New Orleans, held from December 7-11, 2008, the CDC presented malaria and travel vaccine updates. Dr. Paul Arguin from the Domestic Malaria Unit presented "Malaria Update: Surveillance, Prevention, Treatment."
-
Preliminary data from this year's flu season indicates that another mismatch may be occurring between this year's vaccine and the predominant circulating strains of influenza A and influenza B viruses.
-
A randomized, double-blind, placebo-controlled trial conducted in England among 687 children 10-60 months of age with acute virus-associated wheezing compared a five-day course of oral prednisolone (10 m once a day for children 10-24 months of age and 20 mg once a day for older children) with placebo.
-
For this study, 12,765 patients from the large French Hospital Database for HIV with CD4+ lymphocyte counts < 200 cells/uL who received cART during 2000-2005 were selected.
